Genprex Files Registration Statement For Proposed Initial Public Offering
July 21, 2017
AUSTIN, TX, July 21, 2017 – Genprex, Inc. a clinical stage biopharmaceutical company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Genprex intends to apply to list its common stock on the NASDAQ Capital Market, under the ticker symbol “GNPX.”
Network 1 Financial Securities, Inc. is acting as the sole representative of the underwriters.
The offering will be made only by means of a prospectus, which will contain important detailed information about the securities offered. Copies of the preliminary prospectus may be obtained, when available, from the offices of Network 1 Financial Securities, Inc., Attention: Alice McKeon, 2 Bridge Avenue, Building 2, Suite 241, Red Bank, New Jersey, 07701-1106, or by telephone at (732) 758-9001.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Genprex is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.